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Objectives: Reduction in faecal shedding of Shiga toxin-producing enterohaemorrhagic Escherichia coli (EHEC)
in food-producing animals is a viable strategy to minimize human disease initiated by exposure to these microorganisms. To this end, an intervention strategy involving the electrostatic hybridization of two commonly used
anti-infective agents for veterinary practice (i.e. chlorhexidine and ampicillin) was evaluated to curtail EHECtransmitted disease from ruminant sources. Chlorhexidine di-ampicillin is a novel group of uniform material
based on organic salts (GUMBOS) with inherent in vitro antibacterial activity that comes from its parent antimicrobial ions, chlorhexidine and ampicillin.
Methods: Antibacterial activities for chlorhexidine diacetate, sodium ampicillin, chlorhexidine di-ampicillin and
stoichiometrically equivalent 1 : 2 chlorhexidine diacetate : sodium ampicillin were assessed using the serial
2-fold dilution method and time –kill studies against seven isolates of E. coli O157:H7 and one non-pathogenic
E. coli 25922. Further studies to investigate synergistic interactions of reacted and stoichiometrically equivalent
unreacted antimicrobial agents at MICs and possible mechanisms were also investigated.
Results: Synergism and in vitro antibacterial activities against EHEC were observed in this study, which suggests chlorhexidine di-ampicillin could be a useful reagent in reducing EHEC transmission and minimizing
EHEC-associated infections. Likewise, chlorhexidine di-ampicillin reduced HeLa cell toxicity as compared with
chlorhexidine diacetate or the stoichiometric combination of antimicrobial agents. Further results suggest
that the mechanisms of action of chlorhexidine di-ampicillin and chlorhexidine diacetate against E. coli
O157:H7 are similar.
Conclusions: Reacting antimicrobial GUMBOS as indicated in this study may enhance the approach to current
combination drug therapeutic strategies for EHEC disease control and prevention.
Keywords: antibacterial activity, combination drug therapy, chlorhexidine, ampicillin

Introduction
Infections caused by Shiga toxin-producing enterohaemorrhagic
Escherichia coli (EHEC) are associated with bloody diarrhoea,
thrombotic thrombocytopenic purpura, haemorrhagic colitis and
haemolytic uraemic syndrome.1,2 Although strains of EHEC are
represented by several serotypes, the vast majority of severe infections are produced by serotype O157.1,3 Cattle and other ruminants are known to be reservoirs of EHEC and are therefore
known sources for faecal contamination in food and beverages.
As a result, faecal waste from ruminants is associated with large

outbreaks of disease caused by EHEC.4,5 Thus, aside from enforcing
good hygiene practices for all aspects of food handling, i.e. from
harvest to preparation, EHEC transmission may be better controlled by reducing faecal shedding from food-producing
animals.2 Several methods have been tested in attempts to
control the colonization of pathogenic microbes in food-producing
animals, including regulation of animal diet and vaccination. To
date, studies of such control measures to reduce or eliminate
faecal shedding of EHEC in cattle have been inconclusive.4,6 – 8
The current approach to minimizing EHEC faecal shedding in a
food-producing animal involves the use of antiseptics. In this
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chlorhexidine and an antibiotic, ampicillin, was stoichiometrically
synthesized and evaluated for antimicrobial activity and acute
cytotoxicity in comparison with the parent compounds and the
mixture of parent compounds in stoichiometric equivalents to
the GUMBOS.
Since chlorhexidine di-ampicillin GUMBOS is composed of two
separate and distinct antimicrobial agents, it is important to
understand the rationale of how the use of GUMBOS differs
from the mixture of the two parent antimicrobials, such as in
conventional combination drug therapy. Essentially, the two
parent antimicrobial ions (e.g. sodium ampicillin and chlorhexidine diacetate) are strong electrolytes that dissociate completely
in aqueous and some organic solvents. However, the differing dielectric constants of the solvents used to react the parent antimicrobial ions govern the probability of ion association or
GUMBOS formation. For example, higher solvent dielectric constants cause more solvent –ion interactions, whereas solvents
with lower dielectric constants cause more ion –ion associations.24,25 Due to the large dielectric constant of water,
aqueous media create large solvation spheres around antimicrobial ions, which can limit the interaction and subsequent reaction
of the parent ions.24,25 By pre-reacting drug mixtures in solvents
with dielectric constants lower than water, the formation of new
compounds (i.e. GUMBOS or other salts with a low reactivity) can
be facilitated if the parent ions are coadministered using the
combination drug therapy approach. In this regard, the observed
antimicrobial synergy against EHEC and improvements in in vitro
chlorhexidine mammalian cytotoxicity observed with the chlorhexidine di-ampicillin GUMBOS support why conventional combination drug therapy may not achieve similar results.

Materials and methods
Synthesis of chlorhexidine di-ampicillin GUMBOS
A methanolic solution containing stoichiometric amounts of chlorhexidine diacetate and sodium ampicillin, with the latter in slight excess,
was stirred for 2 days at room temperature to ensure the complete formation of chlorhexidine di-ampicillin. After removing methanol using
rotary evaporation, the unreacted starting materials and by-products
were removed from the product by washing several times with cold deionized water. The white product was dried under high vacuum overnight.
The identity and purity of chlorhexidine di-ampicillin were confirmed by
use of various analytical techniques. The structures of chlorhexidine
and ampicillin are shown in Figure 1. See the Supplementary data at
JAC Online for the structural characterization acquired by 1H-NMR
(Figure S1), 13C-NMR (Figure S2), mass spectroscopy (Figure S3 and
Table S1), elemental analysis, circular dichroism (Figure S4) and absorbance spectroscopy (Figure S5).

Antimicrobial activity
Seven strains of E. coli O157:H7 were used in this study (Table S2, available as Supplementary data at JAC Online). Each isolate was grown individually on MacConkey agar with sorbitol for 24 h at 378C. E. coli ATCC
25922 was used as a non-pathogenic strain. All E. coli O157:H7 isolates
were obtained from a collection maintained in the Food Safety/Food
Microbiology Laboratory of Louisiana State University.
Each MIC was determined in triplicate by use of microbroth dilution
essentially as described by Motyl et al.26 Test inocula were prepared
with colonies suspended in saline (0.85% NaCl) and matched to a 0.5
McFarland standard. Cation-adjusted Mueller– Hinton broth (Difco,
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regard, various compounds have been used, some of which have
demonstrated efficacy in the reduction of EHEC in faeces of foodproducing animals. However, many of these compounds are inherently toxic and are not approved for such use in animals.9
One such compound is the dicationic biguanide, chlorhexidine.
Most approved uses of chlorhexidine for cattle include extralabel
topical applications, such as intramammary or terminal recta decolonization therapeutic agents. Under the provisions of the US
Animal Medicinal Drug Use Clarification Act of 1996, various
pharmaceutical agents can be freely used in food-producing
animals beyond the approved labelling at the discretion of the
treating veterinarian, if residues transferred to edible tissues
are below levels of toxicological concern.9 Although subsequent
leaching into adjacent tissues was not part of the study conducted by Naylor et al.,7 chlorhexidine enemas were shown to
eliminate high-level faecal shedding and reduce low-level shedding of E. coli O157:H7 at the terminal rectum. Unfortunately,
it is rather challenging to balance effective concentrations
approved for use in food-producing animals without concern
about possible human exposure to either EHEC infection or
toxic reagents.10 – 13 Therefore, it is important to implement a
therapeutic method that minimizes chlorhexidine toxicity and
maintains its powerful antibacterial activity.
Many antibiotics, such as ampicillin, are also commonly used
in animal feedlots to selectively reduce faecal shedding of EHEC
in ruminants.5 However, the rapid rise of antimicrobial resistance
severely curtails the widespread use of antibiotics in the control
of microbe colonization in food-producing animals.14 Therefore,
approaches that can reduce the concentration of antibiotics
used in animal feedlots would be ideal to minimize the current
contributions they have in the development of antibiotic resistance. Other methods of reducing EHEC faecal shedding have
been explored using FDA-approved ionophores as feed additives.
However, ionophores, such as monensin, lasalocid, laidlomycin
propionate and bambermycin, are known to be ineffective in reducing EHEC shedding in faecal samples, particularly those isolated from sheep.15,16
With the goal of developing a safe and effective compound
that could be administered to food-producing ruminants, such
as cattle, goats and sheep, to reduce faecal shedding of EHEC,
chlorhexidine and ampicillin were combined to form the salt,
chlorhexidine di-ampicillin. These two compounds were chosen
primarily for their history of use in veterinary practice. Integrating
pharmaceutically active ions into entities with other ions that
can modify the properties of pharmaceutically active agents
has been shown to be a realistic approach to resolving many
issues associated with antibiotics, analgesics and antiinflammatory drug therapy.17 – 21
The implementation of designer salts known as a ‘group of
uniform material based on organic salts’ (GUMBOS) is a new
strategy outlined in this article for minimizing the effects of
EHEC. GUMBOS are organic salts composed of organic and/or inorganic counterions with melting points between 25 and 2508C.
These compounds have unique architectural platforms, in that
multimodal properties innate to the desired application can be
incorporated into the salt via judicious selection of the ions.22
In this article, we apply this approach to remedy the toxicity of
chlorhexidine and loss of efficacy present in ampicillin in order
to reduce EHEC faecal shedding in food-producing animals.23
A chlorhexidine di-ampicillin GUMBOS composed of the antiseptic
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Figure 1. Molecular structures of chlorhexidine diacetate (left) and sodium ampicillin (right). Chlorhexidine di-ampicillin consists of two ampicillin
molecules electrostatically tethered to one chlorhexidine molecule. Molecular numbering follows IUPAC nomenclature for each ion, with the
exception of chlorhexidine, where only half is labelled for simplification.

Detroit, MI, USA) with 1% DMSO was used to serially dilute (1: 1) molar
concentrations of chlorhexidine di-ampicillin, sodium ampicillin, chlorhexidine diacetate or the stoichiometric combination of chlorhexidine
diacetate and sodium ampicillin (1: 2, v/v) from 0 to 500 mM. After inoculation, plates were incubated for 24 h at 378C. The MBCs of chlorhexidine
di-ampicillin were determined by plating the clear MIC wells from
microtitre plates onto trypticase soy agar. To eliminate differences in concentration that arise from molecular weight differences, molar concentrations were used to compare the antibacterial activities and for
statistical analysis prior to converting MIC values into mg/L concentrations. This would result in MIC values that are not of standard dilution
concentrations. The antibacterial activity was statistically analysed
(P,0.05) using SAS 9.2 (SAS Institute Inc., Cary, NC, USA).
Loewe’s additivity model was used to evaluate the fractional inhibitory concentration index (FICI) of chlorhexidine diacetate and sodium
ampicillin used in combination.27 – 29 Interaction indices obtained for
the stoichiometric mixture of precursor anti-infectives were compared
with a modified FICI formula that was applied to evaluate chlorhexidine
di-ampicillin ionic interactions in vitro against EHEC. An FICI value of ,0.5
denotes synergy (i.e. the combined effects of two agents are greater than
the sum of their individual effects). If the FICI is ≥0.5 but ≤4, the effect of
the two agents is said to be additive (i.e. the combined effect is equal to
individual activities). If the FICI is .4, then the two agents are considered
antagonistic, meaning the effect of the combined agents is smaller than
that of one of the agents alone. Equations S-1 to S-3 show the Loewe’s
additivity mathematical model used to calculate I values for drug combinations, at an inhibition level of 99.9% (see the supplementary information available as Supplementary data at JAC Online).

Time –kill kinetics of chlorhexidine di-ampicillin
The time–kill kinetics of chlorhexidine di-ampicillin were completed using
a BacLight Live/Dead Assay (Molecular Probes, Carlsbad, CA, USA) as outlined in the established method. More specifically, E. coli O157:H7 ATCC
43895 suspensions were adjusted to 1×108 cfu/mL (optical density at
670 nm of 0.2) and treated with 7.3 mM (MBCGUMBOS) antimicrobial
agent to minimize the 2-fold difference in GUMBOS and chlorhexidine
diacetate molecular weights. The MBC values are equal to 8.7 mg/L
GUMBOS and 4.6 mg/L chlorhexidine diacetate when converted into
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mass per volume concentrations. At different times, aliquots of bacteria
were stained with a fluorescent probe mixture (SYTO 9 and propidium
iodide) and mixed thoroughly. Samples were incubated in the dark for
15 min prior to fluorescence detection. Time–kill behaviour was performed in triplicate and statistically analysed (P , 0.05) using SAS 9.2
(SAS Institute Inc.).

Cytotoxicity assay
To determine cell viability, the colorimetric MTS dye assay (CellTiter 96w
AQueous One Solution Cell Proliferation Assay, Promega, Madison, WI,
USA) was used as an indicator of cell viability. HeLa cells (ATCC CCL-2)
grown in Dulbecco’s modified Eagle’s medium-reduced serum supplemented with 3% fetal bovine serum were plated at a density of
1×104 cells/well into 96-well culture plates (Falcon, Franklin Lakes, NJ,
USA). Doubling dilutions ranging from 3 to 350 mM chlorhexidine
di-ampicillin, chlorhexidine diacetate and sodium ampicillin were used
to treat cells for 24 h at 378C+5% CO2. Cells treated with only medium
served as a negative control. After 24 h of incubation, 40 mL of MTS solution was added to each well and incubated for an additional 1 h. The absorbance intensity was measured using a Perkin Elmer Wallac Victor2 V
Fluorescence/Luminescence Plate Reader (Boston, MA, USA) at 490 nm.
All experiments were performed in quadruplicate and the relative cell viability (%) was expressed as a percentage relative to the untreated control
cells after converting doubly diluted molar concentrations into mg/L. The
cytotoxicity was statistically analysed (P,0.05) using SAS 9.2 (SAS Institute Inc.).

Results
Antimicrobial activity
The antibacterial activities of the reacted chlorhexidine diampicillin GUMBOS were compared with those of chlorhexidine
diacetate, sodium ampicillin and the stoichiometric combination
of the parent salts against EHEC (Table 1). Chlorhexidine
di-ampicillin inhibited the growth of E. coli O157:H7 at concentrations ranging between 0.06 and 0.12 mg/L, with an average
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Table 1. MICs (mg/L) of antibacterial agents
Bacterial strain

Sodium ampicillin

Combination

GUMBOS

E. coli non-pathogenic strain
E. coli 25922

0.19+0.06

2.6+0.37

1.1+0.14

0.36+0.12

E. coli O157:H7 strains
chicken 301C
pork 204P
beef 933
apple cider C7929
hamburger 43895
human 43889
human 43890

0.38+0.03
0.06+0.01
0.25+0.04
0.19+0.04
0.13+0.02
0.19+0.03
0.13+0.02

1.5+0.19
1.9+0.04
2.6+0.04
3.7+0.11
0.7+0.07
3.7+0.04
2.6+0.11

2.7+0.41
0.55+0.14
1.4+0.41
9.6+1.4
0.96+0.14
2.7+0.04
2.7+0.08

0.07+0.02
0.06+0.01
0.09+0.05
0.12+0.05
0.10+0.02
0.07+0.02
0.08+0.02

Standard deviations are from three measurements and statistically analysed at 95% confidence. Combination results refer to the stoichiometric mixture
(i.e. 1 mol chlorhexidine diaceate:2 mol sodium ampicillin) containing fractional inhibitory concentrations equivalent to chlorhexidine di-ampicillin
(GUMBOS) stoichiometry used to compare conventional combination drug therapy approaches with the novel GUMBOS approach. GUMBOS refers to
the reacted chlorhexidine diacetate and sodium ampicillin (i.e. chlorhexidine di-ampicillin) free of sodium acetate by-products.
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Figure 2. Killing kinetics of E. coli O157:H7 ATCC 43895 using 7.3 mM
chlorhexidine di-ampicillin or chlorhexidine diacetate normalized to the
untreated control. Equimolar concentrations equate to 8.7 mg/L
chlorhexidine di-ampicillin and 4.6 mg/L chlorhexidine diacetate. Error
bars represent standard deviations from three measurements.

inhibition observed at 0.08 mg/L. The average MICs of chlorhexidine diacetate and sodium ampicillin were 0.19 mg/L and
2.4 mg/L, respectively. The average inhibitory concentration for
the stoichiometric combination of salts (1 : 2 chlorhexidine diacetate : sodium ampicillin, v/v %) was determined to be 2.9 mg/L.
Thus, chlorhexidine di-ampicillin required a 2 –61× and 7 –120×
lower concentration to inhibit the same growth of E. coli
O157:H7 isolates as compared with sodium ampicillin and the
stoichiometric equivalent of precursor salts, respectively. Although comparable, the antibacterial activity of chlorhexidine
di-ampicillin ranged from 0.5× to 5× more than that of chlorhexidine diacetate, with an average 2.25-fold improvement in MIC.
The growth observed 24 h after plating non-turbid MIC wells
demonstrated that chlorhexidine di-ampicillin is bacteriostatic
at lower concentrations, but bactericidal at concentrations
.8.7 mg/L (108× MIC). Bactericidal rates for chlorhexidine
di-ampicillin and chlorhexidine diacetate were monitored at
the MBC of chlorhexidine di-ampicillin against 106 cfu/mL
(Figure 2). A minimum of 5 h was required to kill 106 cfu/mL

bacteria at 8.7 and 4.6 mg/L for chlorhexidine di-ampicillin and
chlorhexidine diacetate, respectively. Divalent ions were found
to interfere with the membrane activity of both chlorhexidine
di-ampicillin and chlorhexidine diacetate, indicating a probably
similar mechanism of action (data not shown).
Interaction indices for chlorhexidine di-ampicillin are compared with those of the mixture of precursor salts in Table 2.
Chlorhexidine di-ampicillin synergistically inhibited all EHEC isolates (FICIavg¼0.28), whereas antagonism was observed for
the stoichiometric mixture against 28% of the pathogens, respectively. Additivity was observed for chlorhexidine di-ampicillin
and the stoichiometric mixture against non-pathogenic E. coli
ATCC 25922.

Cytotoxicity
Cytotoxicity towards HeLa cells is shown in Table 3. The acute
toxicity (LD50) of chlorhexidine di-ampicillin was determined to
be 142 mg/L. The toxicity of chlorhexidine diacetate, sodium
ampicillin and the stoichiometric chlorhexidine diacetate and
sodium ampicillin mixture was 26, .200 and 98 mg/L, respectively. Thus, exchanging diacetate with di-ampicillin, as evident
in chlorhexidine di-ampicillin, was able to attenuate the associated cytotoxicity of chlorhexidine salts nearly 3 –5× when
used alone or when stoichiometrically combined with sodium
ampicillin. The effective bactericidal and bacteriostatic concentrations of chlorhexidine di-ampicillin are, respectively, 16× and
1775× less than its LD50.

Discussion
Our study shows that chlorhexidine di-ampicillin successfully
inhibited E. coli O157:H7 with greater antibacterial activity than
chlorhexidine diacetate, sodium ampicillin and a stoichiometric
mixture of the two precursor ions when challenged with
several EHEC isolates. When the MIC of chlorhexidine
di-ampicillin was compared with that of the stoichiometric
mixture of commercial chlorhexidine diacetate and sodium
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Table 2. Calculated interaction indices for chlorhexidine di-ampicillin
GUMBOS and the stoichiometric mixture of combined parent salts
Combination
E. coli non-pathogenic strain
E. coli 25922

2.8 (N)

0.9 (N)

1.4 (N)
1.9 (N)
1.2 (N)
10.1 (A)
1.5 (N)
2.0 (N)
5.1 (A)

0.1 (S)
0.5 (S)
0.1 (S)
0.5 (S)
0.3 (S)
0.2 (S)
0.3 (S)

Standard deviations are from three measurements and statistically
analysed at 95% confidence. Classification denoted in parentheses,
where A¼antagonism, N¼neutral and S¼synergy, according to
universal limits established in Odds FC. Synergy, antagonism, and what
the chequerboard puts between them. J Antimicrob Chemother 2003;
52: 1. Combination results refer to the stoichiometric mixture (i.e.
1 mol chlorhexidine diaceate:2 mol sodium ampicillin) containing
fractional inhibitory concentrations equivalent to chlorhexidine
di-ampicillin (GUMBOS) stoichiometry used to compare conventional
combination drug therapy approaches with the novel GUMBOS
approach. GUMBOS refers to the reacted chlorhexidine diacetate and
sodium ampicillin (i.e. chlorhexidine di-ampicillin) free of sodium
acetate by-products.

Table 3. Acute cytotoxicity towards HeLa cells
Antimicrobial agent
Chlorhexidine diacetate
GUMBOS
Combination
Sodium ampicillin

LD50 (mg/L)
26+2
142+3
98+3
.200

Standard deviations are from four measurements and statistically
analysed at 95% confidence.

ampicillin, a maximum 80-fold improvement in antibacterial
activity was observed. This observation advocates that chlorhexidine di-ampicillin GUMBOS would be a more effective antibacterial agent than simply using the two parent agents in
combination or separately for the application of reducing the
transmission of EHEC from the terminal recta of infected ruminants. Likewise, examination of the interaction indices allows
for classification of chlorhexidine di-ampicillin as a synergistic
ionic pair in comparison with the additive and antagonistic
action of the parent salts in mixture. As such, our findings indicate that the coadministration of sodium ampicillin and chlorhexidine diacetate will not achieve similar synergy as observed
with the stoichiometrically reacted chlorhexidine di-ampicillin
GUMBOS. The MBCs of chlorhexidine di-ampicillin and chlorhexidine diacetate were 8.7 and 4.6 mg/L, respectively, which are
concentrations comparable to the effective concentration used
to eradicate EHEC from cattle in a study by Naylor et al.7
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E. coli O157:H7 strains
chicken 301C
pork 204P
beef 933
apple cider C7929
hamburger 43895
human 43889
human 43890

GUMBOS

Time–kill profiles at the chlorhexidine di-ampicillin MBC
(8.7 mg/L, 108× MIC) suggested an initial rapid interaction of
the biocide with cells, resulting in 40% viability in 30 min for
both GUMBOS and chlorhexidine diacetate. Such a quick reduction in cell number has been previously reported for chlorhexidine
salts,30,31 albeit with greater toxicity than our GUMBOS. Examination of the literature supports the rapid yet potent activity of
chlorhexidine salts at inhibitory and bactericidal concentrations.
It is suggested that chlorhexidine salts have a broad concentration range of antibacterial activity in which increasing concentrations cause greater disruption of the bacterium’s osmotic
equilibrium and subsequent intracellular leakage.32
Research from previous antibacterial studies has shown that
the presence of other anionic salts and detergents antagonizes
the antibacterial activity of chlorhexidine salts.33 This was also
found in our antibacterial results consisting of the stoichiometric
mixtures of chlorhexidine diacetate and sodium ampicillin. This
implies that anionic ampicillin can also interfere with chlorhexidine activity when used as an unreacted mixture.31,34 However,
this is not the case with reacted chlorhexidine di-ampicillin,
since synergistic and increased antimicrobial activity over the
mixture was observed. The MICs obtained in this study show
that ampicillin does not interfere with chlorhexidine when
reacted and suggest that the two ions must be functional
without inhibiting the activity of the other, i.e. synergistic.
We also evaluated the effects of divalent cations on the susceptibility of EHEC to chlorhexidine di-ampicillin. It was found
that EHEC susceptibility to chlorhexidine di-ampicillin was attenuated by Ca2+ and Mg2+. These findings suggest that the antibacterial mechanism of action for chlorhexidine di-ampicillin
may involve the displacement of divalent cations, such as
Mg2+ and Ca2+, as similarly observed for chlorhexidine salts.30
Moreover, extraneous divalent cations have been described to
inhibit the outer membrane activity of polycationic salts such
as chlorhexidine. Therefore, we hypothesize that the presence
of excess divalent cations may also repel GUMBOS by inhibiting
its interaction with the lipopolysaccharide (LPS) membrane
layer, disallowing effective cation displacement. Since the MICs
of chlorhexidine diacetate and chlorhexidine di-ampicillin were
comparable for some isolates, we hypothesize that their activities resemble the already established mechanism of action for
chlorhexidine salts containing a bio-inactive counterion (i.e. dihydrochloride, diacetate or digluconate).10,11,13,35 – 39 Studies are
ongoing to identify differences in the mechanisms of action
between chlorhexidine di-ampicillin GUMBOS and chlorhexidine
diacetate and their relationship to the resulting antibacterial activities obtained in this study.
Acute toxicities of chlorhexidine diacetate, sodium ampicillin
and chlorhexidine di-ampicillin were determined in vitro using
HeLa cells. In this study, the LD50 value against HeLa cells was
26 mg/L for chlorhexidine diacetate, which agrees with previously published values. Such concentrations of chlorhexidine have
caused mild to severe inflammatory responses as well as
induced apoptosis, necrosis and overexpression of cellular
stress indicators when used systemically.40 – 43 Reports indicate
that cytotoxicity results in mild to severe discomfort when increasing quantities of chlorhexidine are ingested, although it is
poorly absorbed. Additionally, its use intravenously has caused
hypotonic-induced haemolysis.10 Since examination of the literature suggests that a 2% aqueous concentration of chlorhexidine
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may detrimentally affect host tissues, reducing the apparent toxicity associated with chlorhexidine in the chlorhexidine
di-ampicillin structure is of high priority.
At the LD50 for chlorhexidine diacetate, HeLa cells treated
with chlorhexidine di-ampicillin resulted in 93% viability. More
specifically, the acute toxicity of chlorhexidine di-ampicillin (i.e.
142 mg/L) towards HeLa cells was 5× less toxic than chlorhexidine diacetate. Treating HeLa cells with a stoichiometric equivalent mixture of chlorhexidine diacetate and sodium ampicillin
resulted in a worse LD50 (i.e. 98 mg/L), as compared with the
reacted chlorhexidine di-ampicillin GUMBOS. Thus, our results
suggest that HeLa cells were more sensitive to the toxic effects
of chlorhexidine diacetate when used alone and when used
with sodium ampicillin in the stoichiometric combination. Interestingly, the addition of two ampicillin molecules to the chlorhexidine structure as a mixture or GUMBOS was still able to
reduce the cytotoxic effects of chlorhexidine towards HeLa
cells. This approach demonstrates that the reacted salt, chlorhexidine di-ampicillin, has the potential to extend the antibacterial efficacy of sodium ampicillin while reducing toxicities
associated with chlorhexidine diacetate.
In conclusion, examination of the results of this study suggests that chlorhexidine di-ampicillin may be a viable alternative
to antiseptics and antibiotics in the prevention of E. coli O157:H7
colonization from ruminant reservoirs of infection. More importantly, the levels of potency, reduced toxicity and improved
synergy observed in chlorhexidine di-ampicillin GUMBOS were
not exceeded by the equivalent combination of chlorhexidine
diacetate and sodium ampicillin. Our data also indicate that
chlorhexidine di-ampicillin has bactericidal activity against
EHEC by directly disrupting the outer membrane. This activity is
premised on the displacement of divalent cations from their
binding sites on LPS in the outer membrane. The direct action
of GUMBOS may contribute to its bactericidal activity against
Gram-negative bacteria. Other applications beyond reducing
faecal shedding of EHEC in cattle might be found wherever chlorhexidine is used, e.g. in the prevention of meningitis in neonates
by the eradication of group B streptococci in the vaginas of pregnant women or in the reduction of resistant infections associated
with catheter-induced bacteraemia. Ultimately, the GUMBOS approach represents an alternative strategy to traditional pharmaceutical drug design and conventional combination drug therapy.
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